Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location

被引：0
|
作者：
Kasper, S. [1 ]
Cheng, A-L. [2 ]
Rouyer, M. [3 ]
Foch, C. [4 ]
Lamy, F-X. [5 ]
Esser, R. [6 ]
Batech, M. [7 ]
Wong, C. M. J. [8 ]
Zhang, A. [9 ]
Brodowicz, T. [10 ]
Zielinski, C. [11 ,12 ]
机构：
[1] Univ Hosp Essen Westdeutsches Tumorzentrum, Med Oncol Dept, Essen, Germany
[2] Natl Taiwan Univ, Canc Ctr, Dept Internal Med & Oncol, Taipei, Taiwan
[3] Univ Bordeaux, Bordeaux PharmacoEpi, Bordeaux, France
[4] Merck KGaA, R&D Global Biostat Epidemiol & Med Writing, Darmstadt, Germany
[5] Merck KGaA, Global Epidemiol Dept, Darmstadt, Germany
[6] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[7] Merck KGaA, Med Oncol, Darmstadt, Germany
[8] Cytel Singapore Pte Ltd, Project Based Serv, Singapore, Singapore
[9] Merck Serono, R&D Global Biostat, Beijing, Peoples R China
[10] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria
[11] Vienna Gen Hosp, Comprehens Canc Ctr, Oncol, Vienna, Austria
[12] Med Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.936
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
415P
引用
收藏
页码：S542 / S543
页数：2
相关论文
共 50 条
  • [21] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
  • [22] Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment
    Zheng, Peng
    Ren, Li
    Feng, Qingyang
    Zhu, Dexiang
    Chang, Wenju
    He, Guodong
    Ji, Meiling
    Jian, Mi
    Lin, Qi
    Yi, Tuo
    Wei, Ye
    Xu, Jianmin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (11): : 2337 - +
  • [23] Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer
    Qin, Shukui
    Liu, Tianshu
    Xu, Jianming
    Li, Qi
    Cheng, Ying
    Zhang, Aimar
    Esser, Regina
    Chang, Helena
    Li, Jin
    FUTURE ONCOLOGY, 2023, 19 (15) : 1053 - 1061
  • [24] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [25] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [26] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [28] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [29] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [30] Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer A Randomized Clinical Trial
    Watanabe, Jun
    Muro, Kei
    Shitara, Kohei
    Yamazaki, Kentaro
    Shiozawa, Manabu
    Ohori, Hisatsugu
    Takashima, Atsuo
    Yokota, Mitsuru
    Makiyama, Akitaka
    Akazawa, Naoya
    Ojima, Hitoshi
    Yuasa, Yasuhiro
    Miwa, Keisuke
    Yasui, Hirofumi
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Misumi, Toshihiro
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Yoshino, Takayuki
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (15): : 1271 - 1282
12345